The provision of health care via technology and without direct eye-to-eye and skin-to-skin contact is an area of growing interest in the U.S. It is also an area of great concern. One of the key conundrums surrounding telemedicine is the when, how, and what to pay for the service.
It’s time to revisit billing for Medicare Part B drugs. A proposed demonstration project that every urologist should be aware of, a change in the “brown bag” rules since our last publication, and a continued loss of income by many offices are making the purchase and delivery of drugs less palatable for urology offices.
By now, most of you are relatively fluent in the urology diagnosis codes that affect payment for the services provided in the urology office. Of course, we are now facing the end of the ICD-10 “grace period,” and fears of denials for bad diagnosis codes are once again starting to circulate. This begs the question, what should you do now?